Clinical Trials Logo

Polycythemia clinical trials

View clinical trials related to Polycythemia.

Filter by:

NCT ID: NCT05993065 Recruiting - Polycythemia Vera Clinical Trials

Hematocrit to Hemoglobin Ratio and Red Blood Cell Distribution Width in Polycythemia Vera and Secondary Erythrocytosis.

Start date: December 15, 2022
Phase:
Study type: Observational

Polycythemia vera (PV), a hematological neoplasm characterized by excessive erythropoiesis due to Janus kinase 2 (JAK2)- activating mutations. On the other hand, patients with secondary polycythemia (SP), a disorder mostly caused by an increased red cell mass due to chronic hypoxia (i.e, pulmonary disorders and smoking) and erythropoietin-producing tumors (such as leiomyoma, hemangiomas, renal cysts and various carcinomas), are phenotypically slightly different and are usually considered to have significantly better outcomes. Red blood cell distribution width (RDW) reflects the heterogeneity of red blood cell sizes (anisocytosis) and is routinely reported as a part of complete blood count by automated instruments in hematology laboratories.

NCT ID: NCT05883904 Recruiting - Clinical trials for Primary Myelofibrosis

Real World Evidence of Fedratinib Effectiveness in MF

REALFed
Start date: January 29, 2024
Phase:
Study type: Observational

This is a multicenter prospective and retrospective observational clinical study in patients with primary or post polycythemia vera or post essential thrombocythemia myelofibrosis to test the efficacy of fedratinib in the rea world. Participants will be managed according to the clinical practice of the participating Center. All Centers will be Italian Hematology Units belonging to the GIMEMA Organization in Italy.

NCT ID: NCT05882773 Recruiting - Clinical trials for Primary Myelofibrosis

Asian Myeloproliferative Neoplasm (MPN) Registry

Start date: May 2023
Phase:
Study type: Observational [Patient Registry]

This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.

NCT ID: NCT05870475 Recruiting - Polycythemia Vera Clinical Trials

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

PV
Start date: May 30, 2023
Phase: Phase 2
Study type: Interventional

Study purpose: To compare the efficacy and safety of pegylated interferon α-2b in combination with ruxolitinib versus pegylated interferon α-2b alone for treating hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.

NCT ID: NCT05853458 Recruiting - Polycythemia Vera Clinical Trials

Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors

HU-F-AIM
Start date: July 28, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this study is to confirm the predictive factors for hydroxyurea (HU) failure (hemoglobin (HGB) <15.5 g/dL (9.62 mmol/L) and red cell distribution width (RDW) ≥17%) identified by machine learning in the polycythemia vera advanced integrated model (PV-AIM) project in the real-life setting

NCT ID: NCT05853445 Completed - Polycythemia Vera Clinical Trials

A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera

PAVE
Start date: August 17, 2015
Phase:
Study type: Observational

Jakavi® therapy for polycythemia vera (PV) has so far been studied exclusively in clinical trials and at selected clinical trial centres. This observational study is intended to document the therapy of PV in daily practice with a broad patient population and a geographically representative selection of German centres (both hospitals and practices). The prospective mapping of daily practice reality is thus the main goal of this project.

NCT ID: NCT05835466 Recruiting - Clinical trials for Post Essential Thrombocythemia Myelofibrosis (ET-MF)

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Start date: June 27, 2023
Phase: Phase 2
Study type: Interventional

This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks). After cycle 6, patients may continue receiving reparixin once daily on a 4-week cycle if at least stable disease (SD) is met by IWG-MRT criteria until loss of response, disease progression, unacceptable toxicity, patient/physician withdrawal, or termination of study by sponsor.

NCT ID: NCT05833477 Completed - Erythrocytosis Clinical Trials

Tracing Changed Production of Red Blood Cells

Start date: October 28, 2022
Phase: N/A
Study type: Interventional

In competitive sport, it is illegal to manipulate erythropoiesis. Manipulated erythropoiesis can indirectly be identified by atypical fluctuations in key haematological variables. However, this method also has limitations and as it is known that some athletes still manipulate erythropoiesis it is necessary to develop new and more sensitive detection methods. The primary purpose of the study is to examine the importance of altered erythropoiesis for surface and intracellular erythrocyte proteins, the number of immature reticulocytes, and for the haematological characteristics of the erythrocyte, such as volume, haemoglobin concentration and concentration of glycosylated haemoglobin, to assess whether these can be used to identify changed erythropoiesis. Furthermore, the aim is to examine whether these parameters are affected by freezer storage of erythrocytes.

NCT ID: NCT05714072 Recruiting - Clinical trials for Myelofibrosis Due to and Following Polycythemia Vera

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Start date: January 25, 2023
Phase: Phase 1
Study type: Interventional

The study is being done to see if the combination of ruxolitinib and abemaciclib is a safe and effective treatment for people with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

NCT ID: NCT05566535 Not yet recruiting - Polycythemia Vera Clinical Trials

Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice

QoL-PV-R
Start date: October 1, 2022
Phase:
Study type: Observational

The purpose of this multicenter observational prospective cohort study is to examine changes in QoL and symptoms in patients with polycythemia vera (PV) during treatment with ruxolitinib (Ruxo), and to evaluate efficacy and safety of Ruxo in a real-world setting